In this comprehensive clinical review published by JAMA, experts examine the current evidence for therapeutic cannabis and cannabinoid use, emphasizing implications for clinical practice, risk assessment, and addiction medicine. The authors underscore that while nearly one in four adults report using cannabis or cannabinoids for medical purposes, robust evidence supporting their benefit remains limited for most conditions routinely cited by patients and clinicians. 

Alcohol and other substance use disorders (ASUDs) remain chronic, multifaceted, and undertreated medical conditions with profound individual and societal impacts. Despite compelling advances in neuroscience and evidence-based psychosocial treatments, pharmacotherapies for ASUDs are limited and underutilized in clinical practice. Innovative approaches that bridge metabolic science and addiction biology are critically needed in the addiction treatment landscape. 

ARMR Sciences is preparing to launch the first major human clinical trial of a fentanyl vaccine, marking a potentially transformative development in efforts to prevent opioid overdose and reduce mortality linked to synthetic opioids. Unlike medications such as naloxone that reverse overdoses after they occur, this investigational vaccine is designed as a preventive intervention, training the immune system to produce antibodies that bind to fentanyl molecules in the bloodstream.